← All trials
NCT04134052
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2019
- Primary completion
- Feb 4, 2020
- Completion date
- May 20, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 160
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Universidad de ColimaLead sponsor
- Instituto Mexicano del Seguro SocialCollaborator
- Universidad de ColimaOverall official - principal investigator
- Universidad de ColimaStudy director
- Universidad de ColimaReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.